Equamer capsules 5mg + 10mg + 20mg N30
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Description
Capsules Equamer 5mg + 10mg + 20mg - a combined antihypertensive and lipid-lowering drug (blocker of "slow" calcium channels + angiotensin-converting enzyme inhibitor + HMG-Co-A reductase inhibitor). The composition of the drug Equamer includes three active ingredients - amlodipine, lisinopril and rosuvastatin. The mechanism of action of the drug Equamer is based on the pharmacological properties of active substances.
Active ingredients
Amlodipine + Lisinopril + Rosuvastatin
Composition
Amlodipine besylate 5 mg, lisinopril dihydrate 10 mg, rosuvastatin calcium 20 mg. Adjuvants: microcrystalline cellulose, type 12–86.41 mg, microcrystalline cellulose, type 101–45.27 mg, lactose monohydrate — 96.2 mg, sodium carboxymethyl starch sodium — 17.5 mg, mg, sodium lactose, sodium carbohydrate, 17.5 mg, magnesium, lactose monohydrate, 96.2 mg, sodium carboxymethyl starch sodium — 17.5 mg, mg, magnesium lactose, monohydrate sodium, 17.5 mg, magnesium carboxymethyl starch sodium — 17.5 mg, mg, magnesium lactose, monohydrate, 96.2 mg, sodium carboxymethyl starch sodium — 17.5 mg, mg, magnesium carboxymethyl starch sodium — 17.5 mg, mg, magnesium lactose monohydrate; - 15 mg, magnesium stearate - 3 mg, Opadray II yellow - 4 mg (polyvinyl alcohol 40%, titanium dioxide 23.5%, macrogol-3350 20.2%, talc 14.8%, iron dye yellow oxide 1.5%), hard gelatin capsule - 76 mg (dye azorubine 0.16%, titanium dioxide 1.8519%, gelatin up to 100%).
Indications
Equamer is indicated as replacement therapy in adult patients, whose condition is adequately controlled by the use of amlodipine, lisinopril and rosuvastatin in the same doses as in the preparation Equamer, in the treatment of arterial hypertension and concomitant dyslipidemia: - primary hypercholesterolemia (type IIa by Fredrickson classification, with the exception of familial heterozygous hypercholesterolemia) or mixed hypercholesterolemia (type IIb according to Fredrickson's classification), when diet and other non-drug methods (for example, phe- exercise, weight loss) are not sufficient, - homozygous familial hypercholesterolemia, when diet and other lipid-lowering therapy (eg, LDL apheresis) is not sufficiently effective, - hypertriglyceridemia (Fredrickson type IV according to the classification).
Precautionary measures
In elderly patients, the drug should be used with caution. In clinical studies, no data were obtained on the change in the efficacy or safety profile of amlodipine, lisinopril or rosuvastatin, depending on age.
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation.
Dosage and administration
The drug is taken orally, regardless of the time of meals. The recommended dose of the drug is 1 caps / day. The maximum daily dose is 1 caps. If a dose adjustment is necessary, doses should be titrated using amlodipine, lisinopril and rosuvastatin separately.
Side effects
See instructions
special instructions
Contraindications to the use of angioedema in history, including when using ACE inhibitors, - hereditary or idiopathic angioedema, - severe hypotension (systolic blood pressure less than 90 mmHg), - left ventricular excretory tract obstruction (including severe aortic stenosis), - hemodynamically unstable heart failure after acute myocardial infarction - liver disease in the active phase, including a persistent increase in the activity of transaminases in the blood serum, as well as any increase in the activity of transaminases (more than 3 times compared to VGN), - severe renal dysfunction (CC less than 30 ml / min), - myopathy, - susceptibility to the development of myotoxic complications, - simultaneous use with aliskiren-containing drugs in patients with diabetes or renal insufficiency (GFR less than 60 ml / min / 1.73 m2), - simultaneous use of cyclosporine, - pregnancy, - lactation period (breastfeeding), - use in women who do not use adequate methods of contraception, - children and adolescents under 18 years of age (efficacy and safety not established), - unbearable lactose capacity, lactase deficiency or glucose / galactose malabsorption syndrome, - hypersensitivity to amlodipine or other dihydropyridine derivatives, - hypersensitivity to lisinopril or other ACE inhibitors, - increased sensitivity to rosuvastatin, - hypersensitivity to any of the auxiliary components of the drug.